内科医生和神经科医生知道和认为什么关于catatonia
Japsimran Kaur1, Daniel D Maeng2, Joshua R Wortzel3
1Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
The primary care companion for CNS disorders
|April 18, 2025
概括
内部医生和神经病学家显示,尽管认识到其重要性,但catatonia知识存在差距. 需要改善教育,以提高非精神病学专业中对猫的认识和认可.
科学领域:
- 神经学 神经学
- 内部医学 内部医学
- 精神病学是一个精神病学.
- 医学教育 医学教育
背景情况:
- 卡塔托尼亚是一种可治疗的神经精神综合征.
- 在非精神病学专家中,对白内障的认识和识别是不理想的.
- 需要有针对性的教育干预措施来改善猫的护理.
研究的目的:
- 评估内科医生和神经病学家对猫头的认识和态度.
- 识别理解的差距,并为教育策略提供信息.
- 为了评估一个关于catatonia识别的教育模块的有效性.
主要方法:
- 通过专业网络进行在线调查和教育模块传播.
- 针对内科和神经病学领域的合格从业人员.
- 布什-弗朗西斯卡塔托尼评分表 (BFCRS) 的表现与历史精神病学队列的比较.
主要成果:
- 大多数参与者将形连续症和二类药物确定为一线治疗.
- 教育模块的低完成率 (18%) 尽管对培训的重要性达成一致.
- 与精神病学家相比,内科医生和神经病学家在BFCRS上得分明显较低.
结论:
- 在内科医生和神经病学家之间存在严重的知识差距.
- 对教育材料的低参与度表明潜在的态度障碍.
- 加强教育和宣传活动对于改善Catatonia的识别和管理至关重要.
更多相关视频
10:46Acute In Vivo Electrophysiological Recordings of Local Field Potentials and Multi-unit Activity from the Hyperdirect Pathway in Anesthetized Rats
Published on: June 22, 2017
15.5K
11:05SECONDs Administration Guidelines: A Fast Tool to Assess Consciousness in Brain-injured Patients
Published on: February 6, 2021
14.2K
相关概念视频
Mania and Antimanic Drugs: Overview
101
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
101
Narcolepsy
82
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
82
Disorders of the Nervous Tissue
940
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises...
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises...
940
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
3.0K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
3.0K
The Parasympathetic Nervous System
105.5K
Overview
105.5K
Parkinson's Disease: Overview
310
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
310
